Icahn buys 5 million shares of Biogen Idec

By Lisa Kerner

Charlotte, N.C., Aug. 11 - Biogen Idec Inc. shareholders led by Carl Icahn's High River LP bought approximately 5.07 million shares of the company's stock between Aug. 1 and Aug. 8.

According to a schedule 13D filed with the Securities and Exchange Commission, the shares were priced from $49.97 to $51.50 each.

The investors beneficially own about 17.51 million shares, or 6.03%, of Biogen Idec.

It was previously reported that Icahn put forth a dissident slate of director nominees for election to the Cambridge, Mass., pharmaceutical company's board. Those nominees are Alexander J. Denner, Richard C. Mulligan and Anne B. Young.

In July it was announced that Icahn's nominees were defeated by all four of the company's nominees.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.